<code id='35D4C286DA'></code><style id='35D4C286DA'></style>
    • <acronym id='35D4C286DA'></acronym>
      <center id='35D4C286DA'><center id='35D4C286DA'><tfoot id='35D4C286DA'></tfoot></center><abbr id='35D4C286DA'><dir id='35D4C286DA'><tfoot id='35D4C286DA'></tfoot><noframes id='35D4C286DA'>

    • <optgroup id='35D4C286DA'><strike id='35D4C286DA'><sup id='35D4C286DA'></sup></strike><code id='35D4C286DA'></code></optgroup>
        1. <b id='35D4C286DA'><label id='35D4C286DA'><select id='35D4C286DA'><dt id='35D4C286DA'><span id='35D4C286DA'></span></dt></select></label></b><u id='35D4C286DA'></u>
          <i id='35D4C286DA'><strike id='35D4C286DA'><tt id='35D4C286DA'><pre id='35D4C286DA'></pre></tt></strike></i>

          explore

          explore

          author:Wikipedia    Page View:6213
          Suzanne KreiterGlobe staff

          The state’s celebrated cluster of biotechs has hatched breakthrough medicines for everything from COVID and cystic fibrosis to multiple rare diseases. It has pioneered cutting-edge research in exotic fields like messenger RNA, gene editing, and gene therapies.

          But when it comes to what is arguably the hottest space in drug development today — controlling weight and diabetes for millions of people worldwide — the brainy innovators from Kendall Square have missed out on the booming market, at least so far.

          advertisement

          Instead, the field, which has scientific roots in Massachusetts, is dominated by a pair of global pharma giants: Denmark’s Novo Nordisk, maker of the blockbuster drugs Wegovy and Ozempic, and Indianapolis-based Eli Lilly, which produces the fast-selling Mounjaro.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more
          Medicare Advantage proposed rates disappoint insurers
          Medicare Advantage proposed rates disappoint insurers

          AdobeYou’rereadingthewebversionofHealthCareInc., STAT’sweeklynewsletter followingtheflowofmoneyinmed

          read more
          23andMe had bad news about my health. I wish a person had delivered it
          23andMe had bad news about my health. I wish a person had delivered it

          ERICBARADAT/AFP/GettyImagesLastsummer,IthoughtitmightbefuntohavemyDNAanalyzed.Twocompanies,23andMean

          read more

          Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

          YichuanCao/SipaUSAGileadSciencessaidMondayitwillacquireCymaBayTherapeuticsfor$4.3billion,addinganewt